Author Affiliation: Pediatric, Adolescent and Maternal AIDS Branch, National Institute of Child Health and Human Development, National Institutes of Health, Rockville, Md.
In February 1994, the results of a clinical trial that would change
the face of the pediatric human immunodeficiency virus (HIV) epidemic in the
United States were announced. The trial, Pediatric AIDS Clinical Trials Group
(PACTG) protocol 076, demonstrated that a zidovudine regimen given to HIV-infected
women during pregnancy and labor and to the neonate for the first 6 weeks
of life could reduce the risk of perinatal transmission by two thirds—from
26% in placebo to 8% in zidovudine recipients.1
Mofenson LM. Can Perinatal HIV Infection Be Eliminated in the United States? JAMA. 1999;282(6):577–579. doi:10.1001/jama.282.6.577
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: